In today’s ACT Brief, we examine how AI is moving into continuous clinical operating models, how trust is built into oncology real-world evidence, and how the FDA approved a self-administered option for thyroid eye disease.
News|Podcasts|June 26, 2026
ACT Brief: Bridging Site-Sponsor Data Gaps, Major Study Retraction, and TNBC First-Line Approval
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine integrating site and sponsor data systems, a high-profile trial retraction over integrity concerns, and a new first-line breast cancer treatment.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- Following DIA 2026, Jonathan Andrus, co-CEO of CRIO,
described how central eSource integration can bridge fragmentation between site systems and sponsor oversight. His model combines protocol-driven templates with site-level flexibility, reducing administrative burden while enabling better patient focus. - Nature Medicine retracted a Phase III lung cancer
study after identifying documentation discrepancies, mid-trial protocol changes on ClinicalTrials.gov, and unusual data patterns inconsistent with typical Phase III datasets. The LungTIME-C01 trial claimed dramatic survival benefits from morning immunochemotherapy administration but lacked audit confidence in its integrity. - The FDA
approved Gilead's Trodelvy for first-line metastatic triple-negative breast cancer, both as monotherapy and combined with pembrolizumab. ASCENT-03 showed 38% reduction in disease progression versus chemotherapy, marking the first new backbone therapy for this disease in over two decades.
That's all for today's ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today’s ACT Brief, we examine who decides what trials measure, how designing for human thinking improves site execution, and how the FDA extended an immunotherapy to a new bladder cancer population.
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.
In today’s ACT Brief, we examine what it will take to scale EHR-to-EDC connections for real-time trials, how the FDA is reimagining rare disease drug development, and why oncology real-world evidence still faces persistent data barriers.
In today's ACT Brief, we examine how representation gaps in trials are shaped by structural design decisions, how new partnerships automate data transfer from site systems to sponsor platforms, and how Roche is licensing a novel obesity target from a biotech pioneer.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Trending on Applied Clinical Trials Online
1
Syneos Health, Optum Partner on Adaptive Clinical Development Model
2
Where AI Governance in Clinical Development Falls Short
3
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
4
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
5